The intent of this change is to drive improved health outcomes, which could have substantial benefits and downstream impacts, but if enacted, the proposed changes will expand coverage criteria, significantly impacting health plans in quick time
These data suggest a potential for long-term benefit of liraglutide treatment in many patients, as weight loss of 515% has been shown to improve obesity-related complications including diabetes and cardiovascular disease risk factors [5, 9, 59]
In contrast, long acting GLP-1 receptor agonists have relatively little effect on the rate of gastric emptying due to the development of tachyphylaxis resulting from continuous activation of the GLP-1 receptors in the GI tract (Nauck et al, 2011
Mioduchoski, FNP-BC Karla K
In the end, if we can increase access to these tools while maintaining oversight, and put patient outcomes over profits, that is what will ultimately move the needle on the proverbial scale in the pandemic of excess weight. And Cheng noted that: It is better to use FDA approved treatments rather than experimental and unproven treatments. Moreover, it is important to speak with your healthcare professional regarding the use of GLP-1 or microdosing, he emphasized
